We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Deepverge adds two virus containment laboratories

10 Feb 2021 07:00

RNS Number : 5249O
Deepverge PLC
10 February 2021
 

10 February 2021

 

DeepVerge PLC

("DeepVerge" or "the Company")

 

DeepVerge expands and adds two virus containment laboratories

 

Additional laboratory space added for Skin Trust Club in response to a 95% conversion rate in pre-registration for personalised skincare Home Test Kit in the first 10 days

 

 

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces the addition of two Containment Level 3 (CL3) laboratories at the Company's York, UK HQ facilities, creating a Centre of Excellence for the EcowaterOS consortium, Labskin initiatives, and increases laboratory space in preparation for the launch of the Skin Trust Club, later this quarter.

 

The Centre of Excellence expands on the successful product testing using Labskin with the SARS-CoV-2 virus with University of Aberdeen, Public Health England, University of Liverpool, Cork Institute of Technology and the work completed with industry partners including Dell Technologies, Unilever and the Water Rising Institute. 

 

The CL3 laboratories will be focused on three areas:

 

1. Labskin is a key partner with the Liverpool Tropical School of Medicine and Unilever in a multi-year project, the Strength in Places partnership initiative, to create specialist, commercially sustainable research platforms for infectious disease therapeutics in north-west England. The project will see an expansion of Labskin COVID-19 related services to provide clients with the ability to test their soaps, washes and sanitisers and their effectiveness against COVID-19 and other infectious diseases. 

 

2. Further development alongside partners, such as the Aptamer Group, Tyndall Foundries and a number of undisclosed partners to investigate new variants of SARS-CoV-2 by adding a multiplex nano-chip to test for a range of infectious viruses and bacteria on a single chip for the MicrotoxPD range of equipment for detection and identification of SARS-CoV-2, E.coli, Legionella and Cryptosporidium.

 

3. Continued In-house development of the PulMoBioMed breathalyser condensate on the identification of a variety of respiratory diseases from influenza to SARS-CoV-2, as well as delivering a diagnostic fingerprint for biomarkers relating to diseases where there are no specific and sensitive diagnostic methods available and prognosis is difficult. Further details on this will be provided at a later date.

 

Retrofitting has begun with Modern Water equipment to add to the range of real-time surveillance services in Water Monitoring. New services for Modern Water clients will include standard tests associated with dangerous pathogens, including contagious infections as well as community detection of opioids. Future services will include real-time monitoring and identification of small and large molecules within the pharmaceutical sector during bio-processing.

 

Gerard Brandon, CEO of DeepVerge, commented:

 

"The Centre of Excellence and the addition of two CL3 laboratories, at our York, UK headquarters is the culmination of the successful outcome of handling with SARS-CoV-2 at the University of Aberdeen and the University of Liverpool and used to test dangerous viruses such as Ebola and Lassa as far back as 2015. With Labskin services filling our existing space the 95% conversion rate of pre-registration of the Skin Trust Club is a major achievement and additional space is to be added to accommodate the demand for home test kits which will roll out in March."

 

For further information please contact:

 

DeepVerge plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

Skin Trust Club (www.skintrustclub.com)

 

Note: There is limited availability on pre-registration of Skin Trust Club. Priority will be given to pre-registered users for home test kits at the formal launch. Pre-registration and the downloadable App are free.

 

Customised skincare routine derived from a home test kit, lab tested and linked to local environment via a free smartphone App that updates in real-time and identifies ingredients that suit the subscribers unique skin microbiome. This revolutionises how you take care of your skin with your own skincare routine.

 

Home Test Kit comprises a single swab that maps the skin microbiome delivering a report that produces the most appropriate daily skincare routine based on science, not guesswork. Using real-time air pollution and weather data from the customer's location, the Skin Trust App builds a complete picture of the skin microbiome and the impact of local surroundings.

 

Skin Trust Analysis includes:

· Microbiome identification and quantification of living organisms (bacteria, viruses, bacteriophages, fungi, parasites, etc.) on the skin;

· Skin gene expression analysis to quantify the biological activity of living organisms on the skin ;

· Analysis of metabolites in the skin sample;

· Personal genetic analysis - analyse genomic data to understand potential skin concerns and future risks but does not analyse genes to identify inherited diseases.

 

Labskin (Life Science Division)

Labskin have been pioneering the development of a laboratory grown human skin platform for more than 13 years and is the only commercially available lab-grown full thickness human skin model that naturally mimic the skin's microbiome. With top 20 global consumer health and skincare clients, thousands of industry tests, the good and bad bacteria that naturally exists on human skin is present on Labskin when testing skin care, cosmetics, health care, drug delivery or wound care products. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing products, that shows the positive or negative impact on skin's natural microflora.

 

 

 

Modern Water (Environmental Health Division)

Modern Water is a pioneering and innovative technology subsidiary, and over a 30 year period, with installations in more than 60 countries, this division has built core expertise in the development of analytical instruments and technology for monitoring toxicity in water, soil, food and industry. The core systems use bioluminescent bacteria to perform biosensor testing that detects the presence of toxic substances.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKCBPABKDCBK
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.